Abstract
Mesenchymal stem cell (MSC) immunosuppressive functions make them attractive candidates for anti-inflammatory therapy in allergic asthma. However the mechanisms by which they ensure therapeutic effects remain to be elucidated. In an acute mouse model of house dust mite (Der f)-induced asthma, one i.v. MSC injection was sufficient to normalize and stabilize lung function in Der f-sensitized mice as compared to control mice. MSC injection decreased in vivo airway responsiveness and decreased ex vivo carbachol-induced bronchial contraction, maintaining bronchial expression of the inhibitory type 2 muscarinic receptor. To evaluate in vivo MSC survival, MSCs were labelled with PKH26 fluorescent marker prior to i.v.
injection, and 1 to 10 days later total lungs were digested to obtain single-cell suspensions.
91.5 ± 2.3% and 86.6 ± 6.3% of the recovered PKH26 + lung cells expressed specific macrophage markers in control and Der f mice respectively, suggesting that macrophages had phagocyted in vivo the injected MSCs. Interestingly, only PKH26 + macrophages expressed M2 phenotype, while the innate PKH26 -macrophages expressed M1 phenotype. Finally, the remaining 0.5% PKH26 + MSCs expressed 10 to 100 fold more COX-2 than before injection, suggesting in vivo MSC phenotype modification. Together, the results of this study indicate that MSCs attenuate asthma by being phagocyted by lung macrophages, which in turn acquire a M2 suppressive phenotype.
Introduction
Growing bodies of evidences support the potent role of mesenchymal stem cells (MSCs) in the suppression of exacerbated inflammation [1, 2] . Based on these observations, MSCs are now used in pre-clinical animal models and human clinical trials as an alternative therapeutic strategy to suppress deleterious immune responses in the context of acute graft-versus-host disease [3] , autoimmunity [4, 5] and interestingly in a variety of lung disorders [6, 7] .
Altogether, more than 150 clinical trials have been registered on the NIH clinical trial registry, including the injection of MSCs [8] .
Allergic asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness and deregulated inflammation in response to allergens. This pathology is essentially controlled by CD4 + T helper 2 (T H 2) lymphocytes, which cause cellular infiltration in the lungs, overproduction of mucus and hyper-responsiveness. Some recent reports have highlighted the therapeutic efficacy of MSC injection, in both acute and chronic mouse models of asthma, by notably inducing the production of TGF-β [9] , IL-10 [10] , IFNγ [11, 12] , increasing Treg cell number [13] , and modulating the T H 1-T H 2 immunological balance [11, 14] . However despite these observations, very little is known about the exact mechanisms mediated by MSCs in lung, as the largest part of injected cells does not integrate the lungs [9, 15] . The therapeutic MSC effect has been attributed in part to paracrine effectors [16] including interaction with macrophages [15] via the PGE2 pathway [17, 18] .
In this study, we took advantage of an acute model of house dust mite asthma to evaluate the mechanisms responsible for therapeutic efficacy of MSCs. Our data demonstrate that a single injection of MSCs improved lung function, inhibited contractile response of bronchi, decreased lung inflammation, and MSCs were in vivo phagocyted by lung macrophages which in turn acquired a M2 suppressor phenotype.
Materials and Methods
Protocol -Allergic asthma was induced in 6-to 8-week-old BALB/c mice (Charles River Laboratories) using total Der f extracts (Dermatophagoïdes farinae) provided by Stallergenes as previously described [19] . The Regional Ethical Committee for Animal Experiments of the Pays de la Loire (CEEA.2010.50) approved all animal protocols. In brief, mice were sensitized at day 0, 7, 14 and 21 by percutaneous application of 500µg of Der f extracts in 20µL of dimethylsulfoxide (DMSO, Sigma-Aldrich) on the ears, and challenged intranasally with 250µg of Der f extracts in 40µL PBS at day 27 and 34 ( Fig. 1) . Control mice received only percutaneous application of 20µL DMSO and were challenged intranasally with PBS.
During the first Der f challenge at day 27, mice also received 5. together with either monensin (PMA + ionomycin + monensin; PIM) for T H 17 analysis (2mg/mL; BD Biosciences) or brefeldin A for T H 2 assessment (1mg/mL; BD Biosciences).
For cytokine detection, the FcRs were blocked with mouse CD16/CD32 mAbs (eBioscience).
Prior to surface-specific staining, the cells were stained with Fixable Viability Dye 450 (BD Biosciences) to exclude dead cells. The following antibodies were used for surface staining:
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Results

Mesenchymal stem cells inhibit airway hyper-responsiveness and bronchoconstriction
To investigate the effect of MSC injection on allergic asthma, we used a well-established house dust mite (Der f)-induced asthma model [19] (Fig. 1 in Der f + PBS mice at 20mg/mL methacholine, p=0.03).
As exaggerated bronchial contraction in response to bronchoconstrictor agents is a specific Der f mice injected with PBS displayed a decreased expression of the M2 muscarinic receptor in their bronchi, as compared to control mice injected with PBS or MSCs (Fig. 2C) . In contrast Der f mice injected with MSCs displayed M2 muscarinic receptor expression similar to that of control mice injected with PBS or MSCs. MSCs had no effect on M3 muscarinic receptor expression. Collectively these data suggest that MSCs mediated their protective role in asthma in part by modulating the airway contractile response.
Mesenchymal stem cells are located in lungs after i.v. injection
The presence of MSCs in lungs after i.v. injection was investigated using immuno-histology analysis. MSCs were labelled prior injection with PKH26, a fluorescent red marker which stably incorporates into cell membrane lipids. Successive immunofluorescence and histological analyses showed PKH26 + cell presence in alveolar and capillary walls, both in control and Der f mice (Fig. 3 ). PKH26 + cells were also located in inflammatory infiltrates in
Der f mice (Fig 3, E and F). In both groups PKH26
+ cells were still detected 10 days after
MSC injection (Fig 3, C-D and G-H).
Quantification of mesenchymal stem cells in lungs after i.v injection
One day after injection of PKH26 + labelled MSCs in control and Der f mice, lungs were removed and digested, and lung cell suspensions were evaluated for the presence of PKH26 4D ). Together these data suggest that the vast majority of PKH26 + injected MSCs had been phagocyted by lung macrophages during the 24hr following i.v. injection.
Injection of mesenchymal stem cells decrease airway inflammation
Airway inflammation is another important feature of allergic asthma. The first challenge with
Der f extracts in Der f mice induced the infiltration of both eosinophils and neutrophils in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 12 BAL, associated with the expansion of lung lymphocytes (Fig. 5A) . MSCs did not alter immunologic profile in control mice, suggesting no deleterious effect and no inflammation response due to MSC injection itself (Fig. 5A) . Interestingly, 24 hours after the first Der f challenge (day 28), MSC injection inhibited airway inflammation with decreased absolute numbers of BAL neutrophils, eosinophils and lymphocytes. In parallel a decrease was observed in cytokine (IL-4, IL-5, IL-13 and IL-17) expression by lung CD4 + T cells (Fig. 5B) while no significant effect was observed to IFNγ and IL-10 expression. These data demonstrate that MSCs early constrained airway inflammation, however this suppressive effect declined after a second challenge (data not shown) despite the persistence of decreased hyper-responsiveness ( Fig. 2A) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 13 COX-2, a cyclo-oxygenase which catalyzes the rate-limiting step of prostaglandin formation, Macrophages play an important role in acute allergic lung inflammation [35, 36] , and interaction with macrophages is necessary for an optimal therapeutic effect of MSCs [15] .
MSC injection induces lung macrophage polarization into suppressive phenotype
Depletion of alveolar macrophages reverses the benefit of stem cell treatment [15] and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 increases inflammation [36] . We thus raised the hypothesis that injected MSCs had been MSCs to allergen-sensitized mice resulted in severe pathology [13] . Importantly, the induction of M2 suppressive phenotype was observed in our study only in macrophages that had phagocyted PKH26 + MSCs and not in "naive" macrophages (i.e., PKH26 -macrophages),
suggesting that M2 suppressive phenotype was induced by MSC phagocytosis and not by simple cross-talk between macrophages and MSCs. In summary these data demonstrate that In summary, our data suggest that the mechanism of airway hyper-responsiveness decrease by MSC injection was not limited to a modification of inflammation response as observed in numerous studies [47] , but was also linked to a modification of airway contractility.
Conclusion:
Cell engraftment after i.v injection to repair injured tissue has always been a challenge since the beginning of cell therapy studies. We showed in a mouse model of asthma that most of injected MSCs, not only do not engraft into lungs but are in vivo phagocyted by lung macrophages which, in turn, acquire a M2 suppressive phenotype. This mechanism was sufficient to decrease airway responsiveness and to observe MSC anti-inflammatory efficacy.
As MSCs are being used for their immunomodulatory properties in the treatment of a number of immune-based disorders [48] , further studies on such mechanisms in other models and to unravel early in vivo interactions between MSCs and lung macrophages are warranted. 
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